Online citations, reference lists, and bibliographies.
← Back to Search

Lysosomal Enzyme Replacement Therapies: Historical Development, Clinical Outcomes, And Future Perspectives

M. Solomon, S. Muro
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Lysosomes and lysosomal enzymes play a central role in numerous cellular processes, including cellular nutrition, recycling, signaling, defense, and cell death. Genetic deficiencies of lysosomal components, most commonly enzymes, are known as “lysosomal storage disorders” or “lysosomal diseases” (LDs) and lead to lysosomal dysfunction. LDs broadly affect peripheral organs and the central nervous system (CNS), debilitating patients and frequently causing fatality. Among other approaches, enzyme replacement therapy (ERT) has advanced to the clinic and represents a beneficial strategy for 8 out of the 50–60 known LDs. However, despite its value, current ERT suffers from several shortcomings, including various side effects, development of “resistance”, and suboptimal delivery throughout the body, particularly to the CNS, lowering the therapeutic outcome and precluding the use of this strategy for a majority of LDs. This review offers an overview of the biomedical causes of LDs, their socio‐medical relevance, treatment modalities and caveats, experimental alternatives, and future treatment perspectives. Graphical abstract Figure. No Caption available.
This paper references
10.1523/JNEUROSCI.4785-13.2014
Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A
A. Böckenhoff (2014)
10.1073/PNAS.0506892102
Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.
C. Vogler (2005)
10.1021/acs.molpharmaceut.5b00542
A Comparative Study on the Alterations of Endocytic Pathways in Multiple Lysosomal Storage Disorders.
J. Rappaport (2016)
Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells.
K. Zhao (2000)
10.1166/JBN.2014.1718
Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers.
Janet Hsu (2014)
10.1111/J.1467-7652.2007.00263.X
Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
Y. Shaaltiel (2007)
10.2310/7290.2007.00005
Inflammation-Specific T1 Imaging Using Anti-Intercellular Adhesion Molecule 1 Antibody-Conjugated Gadolinium Diethylenetriaminepentaacetic Acid
Kyu-Sil Choi (2007)
10.1016/j.ymgme.2009.08.003
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
P. Kishnani (2010)
10.1016/j.bbmt.2015.02.011
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
M. Aldenhoven (2015)
10.1038/sj.mt.6300066
Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8-mediated Hepatic Expression of α-galactosidase A.
R. Ziegler (2007)
10.1038/nrm2217
Lysosomes: fusion and function
J. Luzio (2007)
The Hunter corrective factor. Purification and preliminary characterization.
M. Cantz (1972)
10.1248/bpb.b14-00726
Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease.
Y. Tanaka (2015)
10.1172/JCI15420
Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells.
A. Choudhury (2002)
10.1016/J.CHEMBIOL.2005.09.007
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.
A. Sawkar (2005)
10.1089/hum.2014.115
Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.
S. Han (2015)
10.1016/s0021-9258(18)43435-7
Phosphomannosyl-enzyme receptors in rat liver. Subcellular distribution and role in intracellular transport of lysosomal enzymes.
H. D. Fischer (1980)
10.1358/dot.2011.47.7.1608922
Velaglucerase alfa: a new option for Gaucher disease treatment.
A. Zimran (2011)
10.5582/ddt.2016.01024
Recent progress in development of transgenic silkworms overexpressing recombinant human proteins with therapeutic potential in silk glands.
K. Itoh (2016)
10.1096/fj.03-0941fje
Targeting macrophages with baculovirus‐produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis
E. Bonten (2004)
Recombinant human acid beta-glucosidase stored in tobacco seed is stable
S. Reggi (2005)
10.1074/jbc.271.45.28348
Cloning, Expression, Purification, and Characterization of the Human Broad Specificity Lysosomal Acid α-Mannosidase*
Yung-Feng Liao (1996)
10.1017/CBO9780511546198.118
Endothelial Biomedicine: Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1
S. Muro (2007)
10.1038/nbt.1484
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
J. Wang (2008)
10.1016/0076-6879(87)49041-1
Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells.
G. Murray (1987)
10.1074/jbc.274.31.21673
Elevation of Intracellular Glucosylceramide Levels Results in an Increase in Endoplasmic Reticulum Density and in Functional Calcium Stores in Cultured Neurons*
E. Korkotian (1999)
10.1073/pnas.1408556111
ICAM-1 as a molecular target for triple negative breast cancer
P. Guo (2014)
10.1371/journal.pone.0004792
A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation
D. Aviezer (2009)
Lipoprotein receptor binding
W. S. Prince (2004)
10.1016/0003-9861(78)90221-7
Human kidney α-l-Iduronidase: Purification and characterization
L. Rome (1978)
10.1038/8861
Action of BTN1, the yeast orthologue of the gene mutated in Batten disease
D. Pearce (1999)
10.1016/J.BBAMCR.2005.06.009
Secrets of caveolae- and lipid raft-mediated endocytosis revealed by mammalian viruses.
L. Pelkmans (2005)
10.2217/nnm.12.138
Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro.
Ritesh V. Thekkedath (2013)
10.1002/btm2.10050
ICAM‐1‐targeted nanocarriers attenuate endothelial release of soluble ICAM‐1, an inflammatory regulator
R. L. Manthe (2017)
10.1089/HUM.1996.7.4-537
Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II).
C. Whitley (1996)
10.1007/s10545-015-9886-9
Mannose receptor-mediated delivery of moss-made α-galactosidase A efficiently corrects enzyme deficiency in Fabry mice
Jin-Song Shen (2015)
10.1038/cdd.2014.4
High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A
E. Gabandé-Rodríguez (2014)
10.1042/BA20030184
A simple method for the production of recombinant proteins from mammalian cells
C. Wu (2004)
10.1038/NG0795-288
Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease
K. Horinouchi (1995)
10.1073/pnas.2631433100
Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo
Harshad S. Sakhalkar (2003)
10.1146/annurev-med-122313-085916
Lysosomal storage diseases: from pathophysiology to therapy.
G. Parenti (2015)
10.1038/gim.2015.24
Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann–Pick disease type B (acid sphingomyelinase deficiency)
M. Mcgovern (2016)
10.1007/s10038-005-0278-0
Establishment of immortalized Schwann cells from Sandhoff mice and corrective effect of recombinant human β-hexosaminidase A on the accumulated GM2 ganglioside
M. Ohsawa (2005)
10.1007/s00018-015-2105-x
Endocytic membrane trafficking and neurodegenerative disease
A. Schreij (2015)
10.1016/J.JACC.2003.07.048
Intravascular ultrasound molecular imaging of atheroma components in vivo.
A. Hamilton (2004)
10.1016/J.YMGME.2013.12.260
Novel transporters for enzyme replacement therapy
Wenyong Tong (2014)
10.1007/BF02834075
Genetic galactosylceramidase deficiency (globoid cell leukodystrophy, Krabbe disease) in different mammalian species.
K. Suzuki (1985)
Enzyme replacement therapy: conception
R. O. Brady (2003)
10.1016/0006-291X(72)90310-5
A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes.
S. Hickman (1972)
10.1007/s001090050279
Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes
C. Liu (1998)
10.1016/0092-8674(78)90102-2
Human β-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells
D. Achord (1978)
Exploiting shape
A. C. Anselmo (2015)
10.1038/NRG1016
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders
R. Desnick (2003)
10.1161/ATVBAHA.111.244186
Intercellular Adhesion Molecule 1 Engagement Modulates Sphingomyelinase and Ceramide, Supporting Uptake of Drug Carriers by the Vascular Endothelium
Daniel Serrano (2012)
10.3109/10611860903548354
Biopharmaceutical drug targeting to the brain
W. Pardridge (2010)
10.1016/J.YMTHE.2005.07.687
Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.
S. Muro (2006)
10.1016/0378-1119(94)90378-6
Characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A using a baculovirus vector.
G. Coppola (1994)
10.1002/wnan.1157
Recent advances in stealth coating of nanoparticle drug delivery systems.
Z. Amoozgar (2012)
10.1006/PREP.1994.1035
Overexpression of the Human Lysosomal Enzyme α-L-Iduronidase in Chinese Hamster Ovary Cells
E. Kakkis (1994)
A
A. Langford-Smith (2012)
10.1073/PNAS.87.5.1913
Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.
N. Barton (1990)
10.1007/BF00334507
Feline sphingolipidosis resembling Niemann-Pick disease type C
A. Lowenthal (2004)
10.1007/s00253-016-7689-z
α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease
Hong Jai Lee (2016)
10.1016/S0140-6736(03)13311-9
Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I
Revecca Kakavanos (2003)
10.1016/0003-9861(76)90472-0
Clearance of lysosomal hydrolases following intravenous infusion: The role of liver in the clearance of β-glucuronidase and N-acetyl-β-d-glucosaminidase
P. Schlesinger (1976)
10.1093/emboj/cdg629
The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin
S. Lefrancois (2003)
10.1126/scitranslmed.aad9823
Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses
T. Kirkegaard (2016)
10.1016/0014-4886(84)90192-4
A study of intrathecal, cerebrospinal fluid-to-brain exchange
R. Aird (1984)
10.1038/nrm1357
Endothelial cell–cell junctions: happy together
E. Dejana (2004)
10.1038/nature08710
Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology
T. Kirkegaard (2010)
10.1042/BJ2590209
Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties.
J. Bielicki (1990)
10.1126/science.162.3853.570
Hurler and Hunter Syndromes: Mutual Correction of the Defect in Cultured Fibroblasts
J. Fratantoni (1968)
10.1021/bc900382q
Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.
J. Lu (2010)
10.1016/S0168-1656(98)00070-4
Expression of recombinant human acid sphingomyelinase in insect Sf21 cells: purification, processing and enzymatic characterization.
O. Bartelsen (1998)
10.1159/000264398
Blood-brain barrier as a regulatory interface.
W. Banks (2010)
10.1016/S0084-3954(08)70239-2
Transplantation of Umbilical-Cord Blood in Babies With Infantile Krabbe's Disease
J. A. Stockman (2007)
10.1517/17425247.2.5.909
Biomedical aspects of targeted delivery of drugs to pulmonary endothelium
V. Muzykantov (2005)
10.1182/BLOOD-2006-03-010801
Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease.
A. Zimran (2006)
Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells.
E. Kakkis (1994)
10.1073/PNAS.91.26.12937
Enzyme replacement in a canine model of Hurler syndrome.
R. Shull (1994)
10.1021/mp5005959
Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery.
J. Rappaport (2015)
10.2119/molmed.2011.00248
Efficient Uptake of Recombinant α-Galactosidase A Produced with a Gene-Manipulated Yeast by Fabry Mice Kidneys
T. Tsukimura (2012)
10.1016/j.ymgme.2012.02.006
Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.
D. A. Wolf (2012)
10.1172/JCI112262
Trafficking of lysosomal enzymes in normal and disease states.
S. Kornfeld (1986)
10.1038/NM1296-1375
A mouse model for the human lysosomal disease aspartylglycosaminuria
V. Kaartinen (1996)
10.1073/PNAS.95.5.2503
Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure.
Y. Liu (1998)
10.1126/science.1074972
Polymer Vesicles
D. Discher (2002)
10.1073/pnas.0712147105
Chemically modified β-glucuronidase crosses blood–brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII
J. Grubb (2008)
Production in yeast of αgalactosidase a
Y. Chiba (2002)
A study of intrathecal
R. B. Aird (1984)
10.1016/j.jconrel.2015.09.055
Targeted endothelial nanomedicine for common acute pathological conditions.
V. Shuvaev (2015)
10.1016/j.addr.2006.09.009
Multifunctional nanocarriers.
V. Torchilin (2006)
10.1016/s0021-9258(19)70385-8
Structural studies of phosphorylated high mannose-type oligosaccharides.
A. Varki (1980)
10.1128/AEM.00463-07
Production of Recombinant β-Hexosaminidase A, a Potential Enzyme for Replacement Therapy for Tay-Sachs and Sandhoff Diseases, in the Methylotrophic Yeast Ogataea minuta
Hiromi Akeboshi (2007)
10.1074/jbc.M114.628891
Vacuolar ATPase in Phagosome-Lysosome Fusion
Sandra Kissing (2015)
10.1177/030098589703400601
Lysosomal Storage Diseases of Animals: An Essay in Comparative Pathology
R. Jolly (1997)
H
A. G. Bijvoet (1999)
10.1111/J.1432-1033.1994.TB18572.X
Purification, characterization and molecular cloning of human hepatic lysosomal acid lipase.
D. Ameis (1994)
10.1093/glycob/cwp138
Characterization of gene-activated human acid-β-glucosidase: Crystal structure, glycan composition, and internalization into macrophages
Boris Brumshtein (2010)
10.1016/j.jbiotec.2015.04.007
Increased mannosylphosphorylation of N-glycans by heterologous expression of YlMPO1 in glyco-engineered Saccharomyces cerevisiae for mannose-6-phosphate modification.
Jin Young Gil (2015)
10.1042/BST0021014
α-Mannosidase in Zinc-Deficient Rats: Possibility of Liposomal Therapy in Mannosidosis
H. M. Patel (1974)
10.1038/537S162a
Screening: Baby's first test
S. Gupta (2016)
10.1126/science.144321
Mucopolysaccharidosis in a cat with arylsulfatase B deficiency: a model of Maroteaux-Lamy syndrome
P. Jezyk (1977)
10.1038/nm.1876
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium
Emyr Lloyd-Evans (2008)
10.1016/s0021-9258(18)33554-3
Purification and properties of feline and human arylsulfatase B isozymes. Evidence for feline homodimeric and human monomeric structures.
M. Mcgovern (1982)
10.1517/21678707.2013.780970
Emerging therapies and therapeutic concepts for lysosomal storage diseases
T. Kirkegaard (2013)
10.1016/j.ymgme.2014.07.005
Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
J. Murray (2015)
10.1042/BJ2840789
Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase.
D. Anson (1992)
remodeling in a murine model of a lysosomal storage disease
C. S. Stein Tecedor (2002)
10.1038/nrm1423
The cell biology of lysosomal storage disorders
A. Futerman (2004)
10.1056/NEJM199105233242104
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
N. Barton (1991)
10.1093/HMG/9.17.2471
Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel.
M. Sun (2000)
L
P. G. Bloemen (1995)
10.7326/0003-4819-122-1-199501010-00005
Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources
G. Grabowski (1995)
10.1091/mbc.E09-01-0005
Glycolipid Trafficking in Drosophila Undergoes Pathway Switching in Response to Aberrant Cholesterol Levels
R. Hortsch (2010)
10.1038/ki.2011.301
Cysteamine therapy: a treatment for cystinosis, not a cure.
S. Cherqui (2012)
10.1016/j.biomaterials.2010.06.038
Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions.
Spencer Park (2010)
10.1073/PNAS.69.8.2048
The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase.
G. Bach (1972)
10.1124/JPET.103.060236
Dexamethasone-Mediated Up-Regulation of the Mannose Receptor Improves the Delivery of Recombinant Glucocerebrosidase to Gaucher Macrophages
Yunxiang Zhu (2004)
10.1016/J.YMTHE.2006.01.006
Gene therapy for lysosomal storage diseases.
M. Sands (2006)
10.1093/HMG/DDI364
Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase.
S. Tomatsu (2005)
N
T. A. Ratko (2013)
10.1093/HMG/10.16.1639
Enzyme therapy for lysosomal acid lipase deficiency in the mouse.
H. Du (2001)
10.1016/j.ymgme.2008.04.009
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
A. McVie-Wylie (2008)
10.1096/fj.04-2747rev
Nanomedicine: current status and future prospects
S. Moghimi (2005)
10.1111/j.1651-2227.2008.00660.x
CNS‐directed gene therapy for lysosomal storage diseases
M. Sands (2008)
10.1038/nrd1088
The dawning era of polymer therapeutics
R. Duncan (2003)
Recom - binant human acid beta - glucosidase stored in tobacco seed is stable , active and taken up by human fi broblasts
S. Marchetti Reggi
10.1021/bm2003384
pH-responsive polysaccharide-based polyelectrolyte complexes as nanocarriers for lysosomal delivery of therapeutic proteins.
M. I. Giannotti (2011)
10.1074/JBC.M402630200
Lipoprotein Receptor Binding, Cellular Uptake, and Lysosomal Delivery of Fusions between the Receptor-associated Protein (RAP) and α-l-Iduronidase or Acid α-Glucosidase*
W. Prince (2004)
10.1016/j.ymgme.2013.12.003
Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.
Edward I. Ginns (2014)
10.1056/NEJM197411072911901
Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.
R. Brady (1974)
10.1086/498652
The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy.
H. Du (2005)
10.1124/jpet.107.133298
Delivery of Acid Sphingomyelinase in Normal and Niemann-Pick Disease Mice Using Intercellular Adhesion Molecule-1-Targeted Polymer Nanocarriers
C. Garnacho (2008)
Adesnick, The Biogenesis of Membranes and Organelles
M.B.D.D. Sabatini (2001)
ICAM-1-Targeted Nanocarriers Provide Efficient Targeting, Transport across the BBB, and Uniform Distribution and Effects of Therapeutic Enzymes in the Brain, Controlled Release Society
T. Bhowmick (2011)
Human liver iduronate-2sulphatase
J. Bielicki (1990)
Production of recombinant βhexosaminidase a
H. Akeboshi (2007)
10.1194/jlr.R046896
Lysosomal exocytosis and lipid storage disorders
M. Samie (2014)
10.1016/S0014-5793(96)01331-2
Purification of acid sphingomyelinase from human placenta: Characterization and N‐terminal sequence
S. Lansmann (1996)
10.1016/S0169-409X(02)00228-4
Biodegradable nanoparticles for drug and gene delivery to cells and tissue.
J. Panyam (2003)
10.1139/O05-165
Secretion of human glucocerebrosidase from stable transformed insect cells using native signal sequences.
G. Sinclair (2006)
10.1073/PNAS.76.10.5326
Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes.
R. Desnick (1979)
10.1073/PNAS.74.8.3560
Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration.
F. S. Furbish (1977)
10.1074/jbc.M112.357707
δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders*
Miao Xu (2012)
10.1023/B:BOLI.0000031101.12838.c6
Enzyme replacement and enhancement therapies for lysosomal diseases
R. Desnick (2004)
10.1056/NEJM197307052890103
Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease.
R. Brady (1973)
10.1016/J.JPEDS.2004.01.046
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
J. Wraith (2004)
10.1152/AJPLUNG.00311.2005
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins.
S. Muro (2006)
10.1016/s0002-9440(10)63566-3
Viable Mouse Models of Acid β-Glucosidase Deficiency
You-hai Xu (2003)
10.1002/bit.22135
Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouse
R. Boado (2009)
10.1016/J.YMTHE.2005.02.031
Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice.
K. Orii (2005)
10.1016/S0962-8924(00)01847-X
Jamming the endosomal system: lipid rafts and lysosomal storage diseases.
Kai Simons (2000)
10.1124/jpet.107.131318
Identification and Design of Peptides as a New Drug Delivery System for the Brain
M. Demeule (2008)
10.1016/J.BBRC.2005.05.207
Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain.
K. Lee (2005)
10.1016/j.ymgme.2015.11.001
Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
P. Kishnani (2016)
10.3390/10010065
Polymeric Particulates to Improve Oral Bioavailability of Peptide Drugs
F. Delié (2005)
10.1016/j.ymgme.2012.01.019
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.
S. Banugaria (2012)
10.1016/j.bbamcr.2008.08.003
The yeast lysosome-like vacuole: endpoint and crossroads.
S. C. Li (2009)
A human intracellular apyrase-like protein, LALP70, localizes to lysosomal/autophagic vacuoles.
A. Biederbick (1999)
10.1093/GLYCOB/9.12.1389
A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome).
M. Bhaumik (1999)
10.1016/j.jmb.2012.08.020
The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A.
Yadilette Rivera-Colón (2012)
10.1007/s40259-014-0108-z
Elosulfase Alfa: A Review of Its Use in Patients with Mucopolysaccharidosis Type IVA (Morquio A Syndrome)
K. Lyseng-Williamson (2014)
10.1007/s00109-008-0309-3
Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease
U. Matzner (2008)
10.1016/S0378-5173(03)00391-0
Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers.
M. Elsayed (2003)
10.1016/j.ejps.2009.02.008
ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells.
Chuda Chittasupho (2009)
10.1038/NG1095-170
Mouse models of Tay–Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism
K. Sango (1995)
10.1002/bit.24795
Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor
R. Boado (2013)
10.4161/rdis.26690
Clinical studies in lysosomal storage diseases
P. Boudes (2013)
10.1046/j.1471-4159.2002.01201.x
High transcytosis of melanotransferrin (P97) across the blood–brain barrier
M. Demeule (2002)
10.1096/fj.04-2714fje
Protein transduction of Rab9 in Niemann‐Pick C cells reduces cholesterol storage
K. Narita (2005)
10.1016/S0140-6736(75)91517-2
Letter: Identity of cervical dysplasias.
Richart Rm (1975)
10.1016/j.beem.2014.08.005
Non-neuronopathic lysosomal storage disorders: Disease spectrum and treatments.
G. Pastores (2015)
10.1111/tra.12056
Lysosomal Membrane Proteins and Their Central Role in Physiology
M. Schwake (2013)
10.1056/NEJM200101183440304
Enzyme-replacement therapy in mucopolysaccharidosis I.
E. Kakkis (2001)
10.1371/journal.pmed.1002191
What Is the Purpose of the Orphan Drug Act?
M. Herder (2017)
10.1128/MCB.22.21.7622-7632.2002
Intralysosomal Cystine Accumulation in Mice Lacking Cystinosin, the Protein Defective in Cystinosis
S. Cherqui (2002)
10.1073/PNAS.94.6.2540
alpha-Galactosidase A deficient mice: a model of Fabry disease.
T. Ohshima (1997)
10.1089/hum.2008.022
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA.
S. Worgall (2008)
10.1172/JCI34676
Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
P. Dickson (2008)
10.1042/BJ3040043
Recombinant alpha-L-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts.
E. Unger (1994)
10.1096/fasebj.14.10.1265
Lysosome‐related organelles
E. C. Dell'angelica (2000)
10.1074/jbc.M110.150433
X-ray and Biochemical Analysis of N370S Mutant Human Acid β-Glucosidase
R. Wei (2010)
10.1038/mt.2012.214
Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis.
F. Harrison (2013)
10.1093/glycob/cwr157
Production of active human glucocerebrosidase in seeds of Arabidopsis thaliana complex-glycan-deficient (cgl) plants.
X. He (2012)
10.1371/journal.pbio.1002583
Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity
Christopher J. Folts (2016)
FROM CYTASES TO LYSOSOMES.
C. deDuve (1964)
10.1016/J.JPEDS.2005.12.014
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
P. Harmatz (2006)
10.1152/AJPCELL.00099.2003
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress.
S. Muro (2003)
10.1161/01.CIR.98.1.1
Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells.
F. Villanueva (1998)
10.1096/fj.04-2375com
A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder
G. Yam (2005)
10.1016/j.ymgme.2008.10.013
Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
C. Hollak (2009)
10.1073/PNAS.93.25.14821
Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy.
B. Hess (1996)
10.1016/J.YMGME.2008.11.043
42. Wolman disease/cholesteryl ester storage disease: Efficacy of plant-produced human lysosomal acid lipase in mice
H. Du (2009)
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology
D. A. Murrey (2014)
K
B. Hess (1996)
G
A. H. Futerman (2004)
C
A. Biffi (2013)
A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1.
R. Rothlein (1986)
10.1016/0092-8674(75)90002-1
Selection and characterization of eight phenotypically distinct lines of lectin-resistant chinese hamster ovary cells
P. Stanley (1975)
10.1172/JCI111997
Characterization of a new model of GM2-gangliosidosis (Sandhoff's disease) in Korat cats.
E. Neuwelt (1985)
10.1016/S0006-291X(74)80356-6
A recognition marker required for uptake of a lysosomal enzyme by cultured fibroblasts.
S. Hickman (1974)
10.1093/emboj/21.6.1289
Late endosome motility depends on lipids via the small GTPase Rab7
C. Lebrand (2002)
10.1038/14084
Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases
V. Puri (1999)
10.1016/j.ymgme.2015.05.013
Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
M. Wasserstein (2015)
10.1093/HMG/DDH067
Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel.
M. Raychowdhury (2004)
10.1016/j.devcel.2011.07.016
Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance
D. Medina (2011)
K
B. Schmidt (1995)
10.1038/537S151a
Perspective: The rare must become common
M. Patterson (2016)
10.1038/nrd3499
Bio-inspired, bioengineered and biomimetic drug delivery carriers
Jin-Wook Yoo (2011)
10.1016/0092-8674(95)90314-3
A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency
B. Schmidt (1995)
10.1371/journal.pone.0039976
Engineering Yarrowia lipolytica to Produce Glycoproteins Homogeneously Modified with the Universal Man3GlcNAc2 N-Glycan Core
Karen De Pourcq (2012)
Drug delivery and targeting.
R. Langer (1998)
10.1016/j.ymgme.2014.08.002
Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
T. Kizhner (2015)
10.1074/JBC.M309465200
Mannose 6-Phosphate Receptor-mediated Uptake Is Defective in Acid Sphingomyelinase-deficient Macrophages
Rajwinder Dhami (2004)
10.1016/S1474-4422(07)70326-5
Strategies to advance translational research into brain barriers
E. Neuwelt (2008)
10.1002/bies.201100076
Exosome nanotechnology: An emerging paradigm shift in drug delivery
Samira Lakhal (2011)
10.1002/acn3.306
Efficacy and ototoxicity of different cyclodextrins in Niemann–Pick C disease
C. Davidson (2016)
10.1042/BJ1760103
Plasma clearance of glycoproteins with terminal mannose and N-acetylglucosamine by liver non-parenchymal cells. Studies with beta-glucuronidase, N-acetyl-beta-D-glucosaminidase, ribonuclease B and agalacto-orosomucoid.
P. Schlesinger (1978)
10.1016/j.jconrel.2016.07.042
Intra- and trans-cellular delivery of enzymes by direct conjugation with non-multivalent anti-ICAM molecules.
Rasa Ghaffarian (2016)
10.1002/psc.2430
Peptide‐mediated cell penetration and targeted delivery of gold nanoparticles into lysosomes
Chaitali D Dekiwadia (2012)
Neuronal GM1 gangliosidosis in a Siamese cat with beta-galactosidase deficiency.
H. Baker (1971)
10.1016/J.PEDIATRNEUROL.2003.09.003
The status of hematopoietic stem cell transplantation in lysosomal storage disease.
J. Malatack (2003)
10.1016/J.DRUDIS.2006.10.013
Blood-brain barrier delivery.
W. Pardridge (2007)
10.1073/PNAS.0308728100
Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice.
J. LeBowitz (2004)
10.2174/1570161043385736
Endothelial endocytic pathways: gates for vascular drug delivery.
S. Muro (2004)
10.1038/nrm1665
An emergency response team for membrane repair
P. L. McNeil (2005)
Polymer vesicles : Materials science: Soft surfaces
D. Discher (2002)
T
S. Muro (2006)
10.1146/ANNUREV.BI.55.070186.003311
Acidification of the endocytic and exocytic pathways.
I. Mellman (1986)
10.1038/srep29329
Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris
Alexander Rodríguez-López (2016)
10.1016/S0925-4439(97)00036-7
Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models.
D. Brooks (1997)
10.1016/j.ymgme.2008.03.008
Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
T. Ohashi (2008)
10.1002/BIT.21602
Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrier
R. Boado (2008)
10.1016/0304-4165(94)90113-9
Enhanced intracellular stability and efficacy of PEG modified dextranase in the treatment of a model storage disorder.
S. Mumtaz (1994)
10.1111/j.1651-2227.2008.00656.x
Substrate reduction therapy
F. Platt (2008)
10.1002/hep.26289
Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients With cholesteryl ester storage disease
M. Balwani (2013)
Structure of the N-asparagine-linked oligosaccharide units of human placental beta-glucocerebrosidase.
S. Takasaki (1984)
10.1248/BPB.32.786
Glycan engineering and production of 'humanized' glycoprotein in yeast cells.
Y. Chiba (2009)
10.1006/MGME.2001.3173
Purification and Characterization of Recombinant Human Lysosomal α-Mannosidase
T. Berg (2001)
10.1016/J.PROCBIO.2012.07.028
Characterization of a recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in E. coli for enzyme replacement therapy of Morquio A disease
A. Mosquera (2012)
10.3109/1061186X.2010.550921
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B
Alexander Koshkaryev (2011)
10.1093/HMG/8.12.2145
Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II.
A. Bijvoet (1999)
10.1515/9783110685039-030
s ? ? ? ? ? ? ? ? ?
Hung-Yu Tseng (2005)
10.1002/HUMU.20040
Molecular and functional analysis of SUMF1 mutations in multiple sulfatase deficiency
M. Cosma (2004)
Human kidney alpha-L-iduronidase: purification and characterization.
L. Rome (1978)
10.1038/mt.2010.78
Guanidinylated neomycin mediates heparan sulfate-dependent transport of active enzymes to lysosomes.
Stéphane Sarrazin (2010)
10.1083/JCB.93.1.135
Biosynthesis of lysosomal hydrolases: their synthesis in bound polysomes and the role of co- and post-translational processing in determining their subcellular distribution
MG Rosenfeld (1982)
10.1002/ana.20807
Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease
T. Fukuda (2006)
10.1038/360749A0
Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer
J. Wolfe (1992)
Phenotype of arylsulfatase Ade fi cient mice : relationship to humanmetachromat - ic leukodystrophy
P. Saftig B. Hess (1996)
10.1083/JCB.2.4.179
ELECTRON MICROSCOPY OF LYSOSOME-RICH FRACTIONS FROM RAT LIVER
A. Novikoff (1956)
10.1038/gim.2011.4
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
Y. Messinger (2012)
10.1517/17425247.2015.966682
Gene therapy for neurologic manifestations of mucopolysaccharidoses
D. A. Wolf (2015)
10.1016/S0168-3659(01)00218-8
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Y. Li (2001)
10.1016/S0076-6879(00)11075-4
Purification and characterization of recombinant human acid sphingomyelinase expressed in insect Sf21 cells.
S. Lansmann (2000)
10.1016/0076-6879(72)28105-8
[99] α-N-acetylglucosaminidase from hen oviduct
Anthony L. Tabentino (1972)
10.1126/science.1233158
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
A. Biffi (2013)
L
S. Tomatsu (2005)
10.1042/BJ2480755
Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values.
G. Gibson (1987)
10.1242/jcs.00367
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1
S. Muro (2003)
10.1177/0271678X15614589
Pharmacologic manipulation of lysosomal enzyme transport across the blood–brain barrier
A. Urayama (2016)
10.1007/s40778-014-0007-8
Genome Editing: Potential Treatment for Lysosomal Storage Diseases
Talita Giacomet de Carvalho (2014)
10.1016/j.ymgme.2011.02.018
Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
B. Burton (2011)
10.1016/j.celrep.2016.08.033
Reprogramming the Local Lymph Node Microenvironment Promotes Tolerance that Is Systemic and Antigen Specific.
Lisa H. Tostanoski (2016)
10.1073/PNAS.64.1.360
The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation.
J. Fratantoni (1969)
10.1016/j.ymgme.2014.12.300
Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features.
M. Rafi (2015)
10.1016/j.febslet.2010.04.047
Defective cholesterol trafficking in Niemann‐Pick C‐deficient cells
Kyle B. Peake (2010)
10.1016/1046-5928(90)90003-H
Synthesis of a human lysosomal enzyme, beta-hexosaminidase B, using the baculovirus expression system.
J. A. Boose (1990)
10.1083/JCB.119.5.1137
Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion
Y. A. Ioannou (1992)
10.1101/cshperspect.a004804
Lysosomal lipid storage diseases.
H. Schulze (2011)
10.1089/DNA.1988.7.99
Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector.
B. Martin (1988)
10.1016/S0962-8924(00)01794-3
Regulated secretion of conventional lysosomes.
N. Andrews (2000)
10.1111/j.1471-4159.2008.05492.x
Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2
M. Demeule (2008)
Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase.
W. Prince (2004)
10.1038/mt.2012.82
Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.
A. Langford-Smith (2012)
10.1038/mt.2015.189
Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII
B. Gurda (2016)
10.1038/35022604
Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)
I. Nishino (2000)
10.1038/mt.2015.106
Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy.
J. Doerr (2015)
10.1016/0955-0674(94)90069-8
Protein translocation across the endoplasmic reticulum.
P. Walter (1984)
10.1098/RSTB.2003.1269
Enzyme replacement therapy: conception, chaos and culmination.
R. Brady (2003)
10.1016/0006-291X(90)91285-Z
Expression of human lysosomal β-hexosaminidase in yeast vacuoles
T. R. Prezant (1990)
10.2967/jnumed.107.045302
In Vivo Imaging of 64Cu-Labeled Polymer Nanoparticles Targeted to the Lung Endothelium
R. Rossin (2008)
Epidemiology of lysosomal storage diseases: an overview
M. Fuller (2006)
10.1172/JCI118617
Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome.
A. Crawley (1996)
10.1016/j.nano.2011.08.014
Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
Janet Hsu (2012)
10.1002/jcb.22798
Recycling and LFA‐1‐dependent trafficking of ICAM‐1 to the immunological synapse
Jae-Hyeok Jo (2010)
10.1016/S0962-8924(02)02399-1
Endocytosis and sorting of glycosphingolipids in sphingolipid storage disease.
D. Marks (2002)
10.1023/A:1017418800320
The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds., 8th ed., McGraw-Hill, New-York, 2001, 7012 p., $550.00)
C. Scriver (2004)
Genetic galactosylceramidase de fi ciency ( globoid cell leukodystrophy , Krabbe disease ) in different mammalian species
K. Suzuki Suzuki (1983)
10.1073/pnas.0702170104
Targeted delivery of proteins across the blood–brain barrier
B. Spencer (2007)
10.1038/NPG.ELS.0006110
Lysosomal Transport Disorders
G. Mancini (2006)
Novel treatments and future perspectives: outcomes of intrathecal drug delivery.
P. Dickson (2009)
10.1016/j.nbd.2014.02.012
Early axonal loss accompanied by impaired endocytosis, abnormal axonal transport, and decreased microtubule stability occur in the model of Krabbe's disease
C. A. Teixeira (2014)
10.1016/j.biomaterials.2015.07.043
Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: Synergy between physical, chemical and biological approaches.
Aaron C. Anselmo (2015)
10.1089/HUM.2013.238
Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial.
TardieuMarc (2014)
A
B. L. Gurda (2016)
The separation and characterization of subcellular particles.
C. de Duve (1965)
10.1523/JNEUROSCI.0498-13.2013
CLN3 Loss Disturbs Membrane Microdomain Properties and Protein Transport in Brain Endothelial Cells
L. Tecedor (2013)
10.1016/S1046-5928(02)00526-0
Synonymous codon usage bias and the expression of human glucocerebrosidase in the methylotrophic yeast, Pichia pastoris.
G. Sinclair (2002)
10.1055/S-2005-872810
Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities.
B. Hoffmann (2005)
The metabolism of ceramide trihexosides. I. Purification and properties of an enzyme that cleaves the terminal galactose molecule of galactosylgalactosylglucosylceramide.
R. Brady (1967)
10.2147/TACG.S57682
Recent advances in gene therapy for lysosomal storage disorders
D. Rastall (2015)
10.1016/j.cell.2007.10.018
LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase
D. Reczek (2007)
10.1016/S1389-1723(04)00297-X
Production of recombinant human lysosomal acid lipase in Schizosaccharomyces pombe: development of a fed-batch fermentation and purification process.
S. Ikeda (2004)
10.1016/j.jconrel.2012.06.007
Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1.
Rasa Ghaffarian (2012)
10.1007/s00253-014-6328-9
Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A
U. Unzueta (2014)
10.1542/PEDS.113.5.E448
Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human -Glucosidase From Milk
M. Christa (2004)
10.1038/nrn1725
Storage solutions: treating lysosomal disorders of the brain
M. Jeyakumar (2005)
10.1073/PNAS.96.25.14505
Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase.
H. Li (1999)
10.4049/jimmunol.168.1.298
Ceramide-Rich Membrane Rafts Mediate CD40 Clustering1
H. Grassmé (2002)
10.1038/349104a0
Enzyme therapy
R. Abderhalden (1991)
Exosomes Useful to Treat Lysosomal Storage DiseaseGoogle Patents 2016
M. Tarnopolsky (2016)
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3
P. Harmatz (2006)
The twitcher mouse
K. Suzuki (1983)
10.1006/MGME.2000.2979
Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.
C. T. Turner (2000)
10.1083/jcb.201208152
Lysosomal storage disorders: The cellular impact of lysosomal dysfunction
F. Platt (2012)
10.1016/j.ymgme.2009.01.003
Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency.
A. Bradbury (2009)
10.1186/1755-8417-1-6
Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts
M. Cardone (2008)
10.1016/j.ymgme.2015.06.001
Human recombinant lysosomal enzymes produced in microorganisms.
A. Espejo-Mojica (2015)
10.1620/TJEM.136.219
Delivery of fungal beta-galactosidase to rat brain by means of liposomes.
G. Takada (1982)
10.1074/JBC.M108531200
Multiple Signals Regulate Trafficking of the Mannose 6-Phosphate-uncovering Enzyme*
Wang-Sik Lee (2002)
10.1093/HMG/DDI126
Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy.
U. Matzner (2005)
10.2174/138161211797247578
Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
S. Seregin (2011)
10.1038/sj.gt.3302735
Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice
G. Watson (2006)
10.1038/nrm2546
One step at a time: endoplasmic reticulum-associated degradation
S. Vembar (2008)
10.1016/0003-9861(76)90061-8
The relationship of α-l-iduronidase and Hurler corrective factor
L. J. Shapiro (1976)
10.1182/blood-2014-12-615492
In vivo genome editing of the albumin locus as a platform for protein replacement therapy.
Rajiv Sharma (2015)
Isolation and characterization of glucocerebrosidase from human placental tissue.
P. G. Pentchev (1973)
10.1182/blood-2012-09-455238
Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.
J. Boelens (2013)
10.2183/pjab.90.145
Emerging novel concept of chaperone therapies for protein misfolding diseases
Y. Suzuki (2014)
10.1016/S8756-3282(01)00679-2
Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease.
M. A. Monroy (2002)
10.1016/j.ymthe.2017.05.014
Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice.
C. Garnacho (2017)
10.1016/j.addr.2008.04.001
Materials for advanced drug delivery in the 21st century: a focus area for Advanced Drug Delivery Reviews.
H. Ghandehari (2008)
10.1016/J.IJPHARM.2007.10.046
Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides.
A. Jones (2008)
10.1073/PNAS.93.1.65
High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease.
J. van Hove (1996)
10.1093/GLYCOB/CWM008
Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease.
S. M. Van Patten (2007)
10.1016/j.plantsci.2015.08.018
The combination of plant translational enhancers and terminator increase the expression of human glucocerebrosidase in Nicotiana benthamiana plants.
Juthamard Limkul (2015)
10.1042/BJ1450113
Purification of normal human urinary N-acetyl-beta-hexosaminidase A by affinity chromatography.
D. K. Banerjee (1975)
10.1038/ncomms12109
MCOLN1 is a ROS sensor in lysosomes that regulates autophagy
X. Zhang (2016)
10.1371/journal.pone.0046834
The Role of Chaperone-Mediated Autophagy in Huntingtin Degradation
L. Qi (2012)
10.1089/ars.2011.4003
Tight junctions and tissue barriers.
I. Blasig (2011)
10.3171/2013.3.PEDS12397
Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis.
N. Selden (2013)
10.1002/JBM.A.30348
Biological evaluation of calcium alginate microspheres as a vehicle for the localized delivery of a therapeutic enzyme.
C. Barrias (2005)
10.1007/978-94-017-2693-1
Plants as Factories for Protein Production
E. Hood (2002)
10.1002/BIT.20625
Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx.
G. Weller (2005)
10.1002/ajh.21384
Gaucher disease: Resetting the clinical and scientific agenda
P. Mistry (2009)
10.1182/blood-2007-06-098657
RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1.
C. Garnacho (2008)
A
A. C. Lowenthal (1990)
10.1038/nature20414
Defects in trafficking bridge Parkinson's disease pathology and genetics
A. Abeliovich (2016)
10.1073/PNAS.74.5.2026
Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts.
A. Kaplan (1977)
10.1016/J.MOLMED.2003.08.004
Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.
D. Brooks (2003)
10.1002/emmm.201202176
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
C. Spampanato (2013)
10.1542/PEDS.100.6.E11
Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.
R. Brady (1997)
10.1111/pbi.12096
Characterization and downstream mannose phosphorylation of human recombinant α-L-iduronidase produced in Arabidopsis complex glycan-deficient (cgl) seeds
Xu He (2013)
10.1006/PREP.2000.1325
Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A produced in Pichia pastoris.
Y. Chen (2000)
10.1007/s12275-013-2416-2
Low-Scale expression and purification of an active putative iduronate 2-sulfate sulfatase-Like enzyme from Escherichia coli K12
E. D. Morales-Álvarez (2013)
10.1007/s11095-004-1880-0
Pharmacokinetic and Tissue Distribution Mechanism of Mouse Recombinant Heat Shock Protein 70 in Mice
Seiji Takemoto (2004)
10.1016/S0140-6736(71)92435-4
I-cell disease: multiple lysosomal-enzyme defect.
J. Lightbody (1971)
10.1016/j.stemcr.2015.02.022
Ex Vivo Gene Therapy Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse Model
Tagan A. Griffin (2015)
10.1016/j.ceca.2011.03.010
Lysosomal Ca(2+) homeostasis: role in pathogenesis of lysosomal storage diseases.
E. Lloyd-Evans (2011)
10.1016/s0021-9258(18)45483-x
Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-Pick type C fibroblasts.
L. Liscum (1987)
10.1016/j.ymgmr.2014.08.004
Effects of intracerebroventricular administration of 2-hydroxypropyl-β-cyclodextrin in a patient with Niemann–Pick Type C disease
M. Matsuo (2014)
Bio-inspired
J. W. Yoo (2011)
10.1002/ADFM.201600084
Chitosan-Alginate Microcapsules Provide Gastric Protection and Intestinal Release of ICAM-1-Targeting Nanocarriers, Enabling GI Targeting In Vivo.
Rasa Ghaffarian (2016)
10.3410/f.721307679.793515008
Faculty of 1000 evaluation for Getting into the brain: approaches to enhance brain drug delivery.
N. Saunders (2016)
10.1016/S1359-0286(02)00117-1
Biodegradable nanoparticles for drug delivery and targeting
M. Hans (2002)
10.1007/s11103-004-6832-x
Recombinant human acid β-glucosidase stored in tobacco seed is stable, active and taken up by human fibroblasts
S. Reggi (2004)
10.1016/0003-9861(76)90471-9
Clearance of lysosomal hydrolases following intravenous infusion: Kinetic and competition experiments with β-glucuronidase and N-acetyl-β-d-glucosaminidase☆
P. Stahl (1976)
10.1021/ja306866w
The effect of monomer order on the hydrolysis of biodegradable poly(lactic-co-glycolic acid) repeating sequence copolymers.
Jian Li (2012)
10.1080/15548627.2015.1136769
Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases
M. Bourdenx (2016)
10.1172/JCI1722
Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
T. Kikuchi (1998)
10.1038/nbt.2427
A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes
P. Tiels (2012)
10.1096/fj.00-0014com
Infusion of recombinant human acid sphingomyelinase into Niemann‐Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology
S. R. Miranda (2000)
10.1016/J.YMTHE.2005.11.007
AAV transcytosis through barrier epithelia and endothelium.
G. Di Pasquale (2006)
10.1016/0076-6879(91)97180-7
Human acid sphingomyelinase from human urine.
L. Quintern (1991)
10.1042/BJ2890241
Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme.
J. Bielicki (1993)
10.1016/j.bbamcr.2008.12.001
Lysosomal disorders: from storage to cellular damage.
A. Ballabio (2009)
10.1016/j.jconrel.2012.05.052
Challenges in design and characterization of ligand-targeted drug delivery systems.
S. Muro (2012)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1517/14712598.2011.582036
Gene therapy for lysosomal storage disorders
A. Gritti (2011)
10.1016/J.MOLCEL.2004.08.029
GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis.
A. Tessitore (2004)
10.1126/science.174.4011.838
Neuronal GM1 Gangliosidosis in a Siamese Cat with β-Galactosidase Deficiency
H. Baker (1971)
10.1002/adhm.201500746
α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration.
I. Cabrera (2016)
10.1016/S0006-291X(85)80212-6
Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodystrophy (twitcher).
F. Umezawa (1985)
10.1073/PNAS.76.5.2331
Direct demonstration of binding of a lysosomal enzyme, alpha-L-iduronidase, to receptors on cultured fibroblasts.
L. Rome (1979)
10.1038/emboj.2010.237
Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders
A. Fraldi (2010)
A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice.
C. Vogler (1990)
10.4161/bioe.29490
Producing recombinant therapeutic glycoproteins with enhanced sialylation using CHO-gmt4 glycosylation mutant cells
John S Y Goh (2014)
10.1016/j.bbrc.2008.06.021
Sortilin mediates the lysosomal targeting of cathepsins D and H.
M. Canuel (2008)
10.1016/j.psyneuen.2004.04.003
Intranasal insulin improves memory in humans
Christian Benedict (2004)
10.4161/fly.26630
Mutations in palmitoyl-protein thioesterase 1 alter exocytosis and endocytosis at synapses in Drosophila larvae
E. Aby (2013)
Eng,α-Galactosidase A deficiency: Fabry disease
R. J. Desnick (2014)
10.1021/bc200336j
Screening and optimization of ligand conjugates for lysosomal targeting.
I. Meerovich (2011)
10.1182/BLOOD-2004-12-4942
ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow.
L. Yang (2005)
10.1002/cphc.200800296
Oxygen microscopy by two-photon-excited phosphorescence.
Olga S. Finikova (2008)
10.1128/JVI.74.23.11359-11366.2000
Recombinant Human Adenovirus: Targeting to the Human Transferrin Receptor Improves Gene Transfer to Brain Microcapillary Endothelium
H. Xia (2000)
10.1111/J.1601-6343.2005.00336.X
'Smart' delivery systems for biomolecular therapeutics.
P. Stayton (2005)
10.1182/BLOOD.V93.9.2807.409K08_2807_2816
A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease.
B. Friedman (1999)
10.1371/journal.pone.0030341
CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder
P. Calias (2012)
10.1021/acs.bioconjchem.5b00641
Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles.
Makan Khoshnejad (2016)
10.1371/journal.pone.0015054
Cyclodextrin Induces Calcium-Dependent Lysosomal Exocytosis
F. Chen (2010)
10.1016/S0024-3205(02)01917-3
Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus.
B. Sperker (2002)
10.2174/156652306776359522
Cell and gene-based therapies for the lysosomal storage diseases.
B. Hodges (2006)
The uptake of enzymes into lysosomes: an overview.
E. Neufeld (1980)
10.1016/0005-2736(77)90028-1
Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes.
L. D. Steger (1977)
10.1042/BJ1640439
Rapid partial purification of placental glucocerebroside beta-glucosidase and its entrapment in liposomes.
I. Braidman (1977)
10.1056/nejm196608112750606
The sphingolipidoses.
R. Brady (1966)
Action of BTN1
D. A. Pearce (1999)
Expression of recombinant human acid sphingomyelinase in insect Sf21 cells: purification
O. Bartelsen (1998)
10.1124/jpet.105.098970
Endothelial Targeting of High-Affinity Multivalent Polymer Nanocarriers Directed to Intercellular Adhesion Molecule 1
S. Muro (2006)
10.1006/PREP.2000.1230
Purification and Characterization of Recombinant Human α-N-Acetylglucosaminidase Secreted by Chinese Hamster Ovary Cells
K. Zhao (2000)
10.1002/(SICI)1097-4547(19970201)47:3<341::AID-JNR12>3.0.CO;2-4
Delivery of liposome‐sequestered hydrophobic proteins to lysosomes of normal and batten disease cells
N. Ansari (1997)
10.1016/s0021-9258(17)43271-6
Human alpha-L-iduronidase. I. Purification and properties of the high uptake (higher molecular weight) and the low uptake (processed) forms.
E. Schuchman (1984)
10.1093/HMG/5.1.1
Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
D. Phaneuf (1996)
10.1111/all.12155
IgE‐mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome
J. Kim (2013)
10.1016/0304-4165(81)90474-8
Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation.
F. S. Furbish (1981)
Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A.
R. Ziegler (2007)
10.1056/NEJMoa1501365
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.
B. Burton (2015)
10.1042/BJ2590199
Immunopurification and characterization of human alpha-L-iduronidase with the use of monoclonal antibodies.
P. Clements (1989)
10.1371/journal.pone.0156452
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
Marika Salvalaio (2016)
10.1016/j.nbd.2011.01.021
Autophagy failure in Alzheimer's disease—locating the primary defect
R. Nixon (2011)
The twitcher mouse. A model of human globoid cell leukodystrophy (krabbe's disease).
K. Suzuki (1983)
10.1203/01.PDR.0000156510.96253.5A
Joint and Bone Disease in Mucopolysaccharidoses VI and VII: Identification of New Therapeutic Targets and BioMarkers Using Animal Models
C. Simonaro (2005)
10.1096/fasebj.1.6.3315809
Trafficking of lysosomal enzymes 1
S. Kornfeld (1987)
10.1093/GLYCOB/CWF096
Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease.
Y. Chiba (2002)
10.1038/nbt1204-1599
Purification
(2004)
10.1093/pcp/pcn108
Purification, cloning and functional characterization of an endogenous beta-glucuronidase in Arabidopsis thaliana.
Aymerick Eudes (2008)
Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide
D. Serrano (2012)
Enzyme-Replacement Therapies for Lysosomal Storage Diseases
T. Ratko (2013)
10.1093/HMG/6.4.503
Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.
L. Clarke (1997)
10.1177/146642407409400210
(b)
Miss A.O. Penney (1974)
10.1182/BLOOD.V93.6.2081.406K07_2081_2088
Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.
M. Rosenberg (1999)
10.1203/00006450-198410000-00014
β-Glucuronidase Deficiency in a Dog: a Model of Human Mucopolysaccharidosis VII
M. Haskins (1984)
10.1111/j.1471-4159.2007.05030.x
Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain
Xianyang Zhang (2008)
10.1002/9780470122860.CH3
The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins.
G. Ashwell (1974)
10.1093/glycob/cwp080
Production of human beta-hexosaminidase A with highly phosphorylated N-glycans by the overexpression of the Ogataea minuta MNN4 gene.
Hiromi Akeboshi (2009)
10.1096/fasebj.14.2.361
Enzyme replacement therapy in a mouse model of aspartylglycosaminuria
U. Dunder (2000)
10.1016/j.mehy.2014.01.029
Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapy.
G. Baldo (2014)
10.3390/ijms17071065
Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders
M. Coutinho (2016)
10.1515/BC.2009.009
Mannose 6-phosphate receptor-dependent endocytosis of lysosomal enzymes is increased in sulfatide-storing kidney cells
Diana Klein (2009)
10.1042/BJ1290123
Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats.
G. Gregoriadis (1972)
Animal model of human disease: Niemann-Pick Disease type C.
M. Adachi (1976)
10.1089/hum.2013.213
Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease.
R. Ferla (2014)
10.1073/PNAS.72.1.88
A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells.
G. Weissmann (1975)
Alpha - mannosidase in zinc - de fi cient rats . Possibility of liposomal therapy in mannosidosis
H. Onodera Takada (1974)
Early detection of oleic acid-induced lung injury in rats using (111)In-labeled anti-rat intercellular adhesion molecule-1.
R. Weiner (2001)
10.1002/9780470720745.CH8
Steps in the phosphorylation of the high mannose oligosaccharides of lysosomal enzymes.
S. Kornfeld (1982)
10.1152/AJPLUNG.2000.279.3.L419
Mechanisms regulating endothelial cell barrier function.
T. Stevens (2000)
10.1172/JCI116268
Arylsulfatase B-deficient mucopolysaccharidosis in rats.
M. Yoshida (1993)
10.1016/j.jconrel.2010.10.025
Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.
A. J. Calderon (2011)
10.1007/s00018-008-7470-2
Chemical chaperone therapy for GM1-gangliosidosis
Y. Suzuki (2008)
10.5582/irdr.3.1
The current status of orphan drug development in Europe and the US.
A. Hall (2014)
10.1038/nbt0714-599
First CRISPR-Cas patent opens race to stake out intellectual property
C. Sheridan (2014)
10.1038/nature04399
Role of cholesterol and lipid organization in disease
F. Maxfield (2005)
10.1002/jps.21924
Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
S. Dhuria (2010)
10.1016/0006-8993(76)90245-6
Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease
D. Purpura (1976)
10.1007/s10571-004-1375-x
In Search of the Astrocytic Factor(s) Modulating Blood–Brain Barrier Functions in Brain Capillary Endothelial Cells In Vitro
R. Haseloff (2004)
10.1002/wnan.73
New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.
S. Muro (2010)
10.1016/0014-5793(94)01350-A
Adhesion molecules: a new target for immunoliposome‐mediated drug delivery
P. Bloemen (1995)
10.1007/springerreference_109779
[Niemann-Pick disease types A and B].
K. Ohno (1995)
10.1576/toag.9.3.177.27338
Cloning
Alison Murdoch (2007)
10.1182/blood-2010-04-278234
Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.
Ilaria Visigalli (2010)
10.1074/JBC.M500835200
Rhinoviruses Infect Human Epithelial Cells via Ceramide-enriched Membrane Platforms*
H. Grassmé (2005)
10.2174/1874285801610010124
Bioinformatic Analysis of the Human Recombinant Iduronate 2-Sulfate Sulfatase
E. D. Morales-Álvarez (2016)
10.1073/PNAS.91.21.9975
Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease.
S. Yamanaka (1994)
10.1016/J.YMGME.2012.11.082
Production of human recombinant alpha-N-acetylglucosaminidase enzymes in two Pichia pastoris strains
A. Espejo-Mojica (2013)
10.1002/ddrr.1117
Newborn screening for lysosomal storage disorders and other neuronopathic conditions.
D. Matern (2013)
10.1038/mt.2008.127
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.
S. Muro (2008)
10.1089/humc.2013.208
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates.
Darren A Murrey (2014)
10.1016/S1734-1140(09)70004-0
ICAM-1 signaling in endothelial cells.
C. Lawson (2009)
10.1080/15216549600201841
Expression of catalytically active human multifunctional glycogen‐debranching enzyme and lysosomal acid alpha‐glucosidase in insect cells
J. Wu (1996)
10.1194/jlr.R047837
Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin
J. Vance (2014)
10.1186/s13023-015-0262-5
Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act
K. Mechler (2015)
10.1016/S0169-409X(01)00141-7
Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo.
J. Schnitzer (2001)
10.1038/346425A0
Adhesion receptors of the immune system
T. Springer (1990)
10.1007/s13346-012-0072-4
Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders
S. Muro (2012)
10.1021/mp500241y
Clathrin-Mediated Endocytosis Is Impaired in Type A–B Niemann–Pick Disease Model Cells and Can Be Restored by ICAM-1-Mediated Enzyme Replacement
J. Rappaport (2014)
10.1038/mt.2008.84
Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse.
A. Urayama (2008)
α-Galactosidase A deficiency. Fabry disease
R. Desnick (2001)
10.1038/ncomms1735
Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release.
Dongbiao Shen (2012)
H
R. Ghaffarian (2016)
K
S. Kissing (2015)
Y
R. J. Boado (2009)
10.1093/GLYCOB/6.4.471
Role of complex asparagine-linked glycans in the allergenicity of plant glycoproteins.
G. García-Casado (1996)
10.1016/j.addr.2009.08.001
Polymer therapeutics: clinical applications and challenges for development.
M. Vicent (2009)
10.1074/jbc.M110.134775
Exosome Secretion Ameliorates Lysosomal Storage of Cholesterol in Niemann-Pick Type C Disease*
K. Strauss (2010)
10.1016/j.jconrel.2010.10.031
Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Janet Hsu (2011)
10.1038/90242
The HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed from recombinant viral vectors
H. Xia (2001)
10.2174/138161208784705504
Lysosomal storage diseases and the blood-brain barrier.
D. Begley (2008)
10.5414/CPP47100
Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
E. Miebach (2009)
10.1111/j.1600-0854.2006.00429.x
The Lysosomal Trafficking of Acid Sphingomyelinase is Mediated by Sortilin and Mannose 6‐phosphate Receptor
X. Ni (2006)
10.1038/ncomms2070
Production of α-L-iduronidase in maize for the potential treatment of a human lysosomal storage disease.
Xu He (2012)
10.1016/s0021-9258(18)67420-4
Lec1A Chinese hamster ovary cell mutants appear to arise from a structural alteration in N-acetylglucosaminyltransferase I.
W. Chaney (1986)
10.1371/journal.pone.0049635
Acidic Nanoparticles Are Trafficked to Lysosomes and Restore an Acidic Lysosomal pH and Degradative Function to Compromised ARPE-19 Cells
Gabriel C. Baltazar (2012)
10.1242/jcs.034298
Inhibitors of the V0 subunit of the vacuolar H+-ATPase prevent segregation of lysosomal- and secretory-pathway proteins
J. A. Sobota (2009)
10.1201/b13564-107
Gaucher disease.
R. V. Van Tiggelen (1989)
10.2174/187152006778699095
New generation of liposomal drugs for cancer.
T. Minko (2006)



This paper is referenced by
10.5772/intechopen.90097
Technology, Science and Culture - A Global Vision, Volume II
Sergio Picazo-Vela (2020)
10.1080/1061186X.2017.1374390
Lysosomal targeting strategies for design and delivery of bioactive for therapeutic interventions
Ankur A Sharma (2018)
10.1016/j.ymgme.2020.04.002
Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience
A. Sechi (2020)
10.1016/j.ymgmr.2020.100639
Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor
Minori Kanzaki (2020)
10.1016/j.freeradbiomed.2019.09.008
High-effective reactive oxygen species inducer based on Mn-tetraphenylporphyrin loaded PLGA nanoparticles in binary catalyst therapy.
Maria Faustova (2019)
10.15171/bi.2018.17
Enzyme replacement therapies: what is the best option?
A. Safary (2018)
10.1038/s41467-019-09809-3
The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells
W. Tian (2019)
10.3390/biomimetics3030019
Alterations in Cellular Processes Involving Vesicular Trafficking and Implications in Drug Delivery
S. Muro (2018)
10.1007/s10334-018-0723-7
Dissociation of 19F and fluorescence signal upon cellular uptake of dual-contrast perfluorocarbon nanoemulsions
P. Bouvain (2018)
10.1007/978-981-15-7590-7_1
Large Biomolecules: An Overview
B. K. Behera (2020)
10.3390/ijms19051500
Alpha-Mannosidosis: Therapeutic Strategies
M. R. Ceccarini (2018)
10.20944/preprints201910.0365.v1
Pharmacological Chaperones for the Mucopolysaccharidoses
Juan Camilo Losada Diaz (2019)
10.1016/j.addr.2017.10.006
Enzyme prodrug therapies and therapeutic enzymes.
B. Städler (2017)
10.1080/21678707.2019.1684258
Advances in the treatment of neuronal ceroid lipofuscinosis
Jonathan B. Rosenberg (2019)
10.2174/1389203719666180926121722
The Place for Enzymes and Biologically Active Peptides from Marine Organisms for Application in Industrial and Pharmaceutical Biotechnology.
Jean-Étienne R L Morlighem (2019)
10.2174/1381612825666190708213159
New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
M. R. Gigliobianco (2019)
10.1039/C9TB00181F
Albumin enhances dextran NP’s delivery and therapeutic efficacy of PTX for colorectal cancer
X. Zhang (2019)
10.3390/ijms21010232
Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses
Juan Camilo Losada Díaz (2019)
10.3390/molecules23061289
Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review
Isra' Zeiadeh (2018)
10.1080/1061186X.2019.1630415
Gene therapy for neurological disorders: challenges and recent advancements
Stefanie A Pena (2019)
10.1016/j.addr.2020.07.026
Application of advances in endocytosis and membrane trafficking to drug delivery.
Yaping Ju (2020)
10.1016/S1474-4422(19)30143-7
Diagnosis, prognosis, and treatment of leukodystrophies
M. S. Knaap (2019)
10.1186/s13023-019-1220-4
Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective
Shanice Beerepoot (2019)
10.1124/jpet.119.257345
δ-Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?
R. L. Manthe (2019)
10.1016/j.mcn.2020.103540
Role of induced pluripotent stem cells in lysosomal storage diseases
J. Kido (2020)
10.1093/database/baz112
RareLSD: a manually curated database of lysosomal enzymes associated with rare diseases
Sana Akhter (2019)
10.1016/j.lfs.2018.03.018
Pharmacokinetics and pharmacodynamics of PEGylated truncated human cystathionine beta‐synthase for treatment of homocystinuria
Tomas Majtan (2018)
10.1016/j.jgg.2018.02.001
Current strategies for the treatment of inborn errors of metabolism.
M. Gambello (2018)
10.1007/s40265-020-01440-7
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy
N. Specchio (2020)
10.1080/09723757.2017.1365433
Gaucher’s Disease and Hurler’s Syndrome in Two First Cousins
Patricia Fenton-Navarro (2017)
10.1016/j.heliyon.2020.e03635
A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia
María Alejandra Puentes-Tellez (2020)
10.1101/mcs.a002147
Utility of rapid whole-exome sequencing in the diagnosis of Niemann–Pick disease type C presenting with fetal hydrops and acute liver failure
Mersedeh Rohanizadegan (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar